<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main"></title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2014-07-04">04 July 2014</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xin-Hai</forename><surname>Hu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Henning</forename><surname>Cammann</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Medical Informatics</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">People&apos;s Hospital</orgName>
								<address>
									<settlement>Changzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hellmuth-A</forename><surname>Meyer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Klaus</forename><surname>Jung</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Berlin Institute for Urologic Research</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hong-Biao</forename><surname>Lu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Urology</orgName>
								<address>
									<settlement>Changzhou No</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Natalia</forename><surname>Leva</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">Stanford University School of Medicine</orgName>
								<address>
									<settlement>Stanford</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ahmed</forename><surname>Magheli</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carsten</forename><surname>Stephan</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Berlin Institute for Urologic Research</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>Dr</roleName><forename type="first">Jonas</forename><surname>Busch</surname></persName>
							<email>jonas.busch@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hu</forename><surname>Xh</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Meyer</forename><surname>Ha</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lu</forename><surname>Hb</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephan</forename><forename type="middle">C</forename><surname>Busch</surname></persName>
						</author>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2014-07-04">04 July 2014</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.4103/1008-682X.129940</idno>
					<note type="submission">Received: 29 October 2013; Revised: 08 December 2013; Accepted: 22 January 2014</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-14T00:58+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>artificial neural network</term>
					<term>prostate cancer</term>
					<term>recurrence</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Artificial neural networks imitate learning processes and interactions between human neurons. 8 During the training phase, it gradually reduces the deviation of prediction by learning the relationships among inputs (variables) and outputs (prediction results) as well as relationships between the input variables. Finally, the ANN has the ability to predict the probability of BCR. Opinions vary regarding the comparison between ANN and LR. 9-14 Most criticism arises from the limited prediction accuracy due to limitations of the algorithm. 15,16 LR is a special form of ANN. If the relationships among input parameters are nonlinear, ANN models will perform better than LR. Otherwise, the LR is preferable because the influence of each parameter can be observed much easier than in ANNs. In this study, we describe the suitability of ANNs as a prediction tools for BCR. Evaluation of the ability of a computer model to predict of BCR after radical prostatectomy is mainly based on the following parameters: the accuracy of the predicting models, the universality of the internal/external validation, correction capability, complexity, and clinical value. 17 Here, we analyzed ANN and LR performance in predicting BCR based on these criteria. In addition to the ANN and LR models immediately after surgery, we analyzed ANN and LR models that evaluate BCR risk at 6-month intervals, which allows for a more</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p>Prostate-specific antigen (PSA) is a widely accepted screening parameter for early detection of prostate cancer (PCa). Treatment of localized PCa is often performed by radical surgery such as laparoscopic radical prostatectomy (LRP). <ref type="bibr" target="#b0">1</ref> The PSA value in most patients will drop to zero within 2 months after LRP. A consecutive increase of serum PSA up to 0.1 or 0.2 ng ml −1 is defined as biochemical recurrence (BCR). <ref type="bibr" target="#b1">2</ref> BCR is considered a predictor of clinical recurrence and metastasis of PCa. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4</ref> Therefore, early identification and treatment of BCR is important to improve the long-term survival.</p><p>Presently, Gleason Score (GS), preoperative PSA, and pathological stages (pTs) are the main parameters used to predict the risk of BCR. <ref type="bibr" target="#b4">5</ref> For higher accuracy and specificity; multivariate logistic regression (LR) models such as nomograms <ref type="bibr" target="#b5">6</ref> have been used to improve prediction. Most applications of LR in BCR prediction are available with standard nomograms, but there are only few artificial neural networks (ANNs) available for BCR prediction <ref type="bibr" target="#b6">7</ref> and none is freely available online. Further, there are no available models that calculate the individual BCR free probability at multiple time-points after operation especially after different time periods without BCR.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ORIGINAL ARTICLE</head><p>Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score accurate prediction of BCR at any given time after surgery. ANN has already been described as a good alternative to Cox and other regression models. <ref type="bibr" target="#b17">18</ref> From a practical point of view, there is an urgent need for tools that provide information on recurrence-free survival (FS) at distinct time points after radical prostatectomy taking into account the already elapsed recurrence-free interval.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p>Between 1999 and 2007, 1897 PCa patients underwent LRP at our institution. Among them, 322 patients were lost to follow-up or had to be eliminated due to neo-adjuvant hormonal therapy or largely incomplete datasets. The remaining 1575 patients were divided into two groups: 1300 patients (82.5%) with no evidence of BCR (nonBCR) and 275 patients (17.5%) with BCR (BCR group). The median follow-up period was 82.1 months (range from 0.2 to 129.5).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data collection</head><p>Biochemical recurrence was defined as serum PSA levels greater than 0.1 ng ml −1 at two consecutive time points. All preoperative blood samples were measured by Immulite® 2000 assays (Siemens Healthcare, Erlangen, Germany). Data collection included: age, PSA, free/total PSA (%fPSA), prostate weight, digital rectal examination (DRE) status, pT, <ref type="bibr" target="#b18">19</ref> margin status (positive surgical margin <ref type="bibr">[PSM]</ref> or negative surgical margin <ref type="bibr">[NSM]</ref>) and GS. <ref type="bibr" target="#b19">20</ref> For the parameter distribution analysis, pTs of the prostatectomy specimens were classified into pT2, pT3/4; GS &lt;7, GS =7, GS &gt;7; PSM or NSM; positive DRE or negative DRE. PSA, margin status, pT and GS were used for ANN and LR analysis.</p><p>This study was conducted under a local Ethics Committee approved protocol and obeys Reporting of Diagnostic Accuracy guidelines. <ref type="bibr" target="#b20">21</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>Artificial neural network and LR models were computed using the MATLAB-software and the Neural Network Toolbox (Mathworks, Natick, MA, USA). Each ANN (feed forward network with error back propagation) had three layers: input layer with four neurons, hidden layer with two neurons and output layer with one neuron representing the nonBCR probability. Follow-up data after LRP were collected every 6 months and respectively added into the separate models. Every 6 months separate models (ANN and LR) were calculated with those patients still not having a BCR at this time-point (those with a BCR earlier were excluded) and those who were not censored. For all models, internal validation was performed with the leave one out method.</p><p>Statistical analysis was performed using SPSS 19.0 (IBM, Chicago, IL, USA) and MedCalc 12.4.0 (MedCalc Software, Mariakerke, Belgium) to compare all variables using receiver operating characteristic (ROC) analyses regarding sensitivity, specificity and areas under ROC curve (AUC). The comparison of ROC curves were performed with the method of Delong and the comparison of prediction results were conducted using Mann-Whitney U test for continuous variables and Fisher's exact test for ordinal variables. Differences were considered statistically significant if P &lt; 0.05. <ref type="table" target="#tab_0">Table 1</ref> displays the patient characteristics as well as the distribution of clinico-patholological parameters of the BCR and nonBCR group. There were no relevant differences between the two groups for age (P = 0.37), PSA (P = 0.12), %fPSA (P = 0.26), prostate volume (P = 0.33), and PSA density (P = 0.11). In contrast, the pathological GS, margin status, and pT were different between the BCR and nonBCR group except for GS =7 (P = 0.12), as shown in <ref type="table" target="#tab_0">Table 1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Baseline characteristics</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Receiver operating characteristic analysis of selected parameters</head><p>Specificities of the BCR prediction results computed by ANN and LR models with the PSA, margin status, pT, and GS directly after LRP were the highest at both sensitivity cutoffs of 90% and 95%, as shown in <ref type="table" target="#tab_1">Table 2</ref>. GS and PSA showed lower specificities and lower AUCs than ANN and LR. <ref type="figure" target="#fig_0">Figure 1</ref> clearly shows the larger AUCs of the two models compared with GS and PSA alone. <ref type="table" target="#tab_3">Table 3</ref> displays the pairwise comparison of all parameters. While ANN and LR were not different (P = 0.39), ANN and LR predicted BCR better than PSA or  GS (P = 0.0015 for ANN vs GS and P &lt; 0.0001 for ANN vs PSA, LR vs GS and vs PSA, respectively). <ref type="figure" target="#fig_1">Figure 2</ref> displays probabilities for BCR-FS up to 2.5, 5, and 7.5 years after LRP for different categories of GS and ANN outputs. PCa patients with GS &lt;7 always have the highest probability for BCR-FS compared with patients with GS =7 or GS &gt;7 <ref type="figure" target="#fig_1">(Figure 2a-2c)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biochemical recurrence-free survival curves</head><p>In predicting BCR-FS, ANN, and LR perform similarly (LR data not shown). To allow better differentiation of patients who more urgently may need adjuvant radiation (and hormonal treatment) we subdivided all patients using the continuous ANN output values and separated them into two groups below and above the median. This median output was calculated from the 1575 ANN output values according to the prevalence of nonBCR. <ref type="figure" target="#fig_1">Figure 2d-2f</ref> shows the difference between patients above and below the median ANN output values with up to 2.5, 5, and 7.5 years of follow-up.</p><p>Analysis of individual ANN output values had no benefit in patients with a GS &lt;7 PCa but it improved the prediction for all patients with GS ≥7. Of all 1026 PCa patients with GS ≥7, 235 (23%) had a BCR ( </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>Different types of ANNs have been used for a variety of purposes in management of PCa. For example, PSA, prostate volume, DRE, and other variables are used as input parameters for diagnosing PCa. <ref type="bibr" target="#b21">22</ref> ANN is also used to predict the outcome of repeat prostate biopsies, <ref type="bibr" target="#b22">23</ref> and furthermore, to predict the risk of lymph node metastasis in PCa patients. <ref type="bibr" target="#b23">24</ref> However, ANN applications to predict BCR are rare. <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b9">10</ref> Our data on BCR prediction show that ANN and LR models including the parameters PSA, margin status, pT and GS, can correctly simulate and reflect interactions between variables in the training set. The models improve the prediction better than any single variable and thus estimate BCR more accurately for each individual patient with PCa. <ref type="bibr" target="#b24">25</ref> Some studies have verified that ANN models have the ability to improve prognosis prediction for PCa patients after prostatectomy. <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref> These data have been summarized in <ref type="table" target="#tab_4">Table 5</ref>. One of the first studies in 1994 demonstrated 87% accuracy. <ref type="bibr" target="#b25">26</ref> Among all available studies to date, the results by Tewari et al. <ref type="bibr" target="#b6">7</ref> showed the best AUC with 0.83; however, their accuracy was somewhat lower than in the present study and in other studies. Potter et al. <ref type="bibr" target="#b25">26</ref> gained similar AUCs of 0.71, 0.74, 0.74 using different input parameters, but the specificity was relatively lower than in our present study. However, despite large differences in sensitivity and specificity levels there are relatively small accuracy ranges (70%-87%) and AUCs between 0.71 and 0.83 for all studies. This demonstrates that the parameters that were used do not allow a better prediction of BCR. Interestingly, PSA has been thought to improve prediction of BCR following PCa diagnosis; <ref type="bibr" target="#b29">30</ref> however in our study, %fPSA did not improve prognosis. The median values were not different between the non-BCR and BCR group (10.7 vs 9.2%; P = 0.26) ( <ref type="table" target="#tab_0">Table 1</ref>).</p><p>An important finding was the additional benefit of our ANN for patients with aggressive PCa (GS ≥7). Among 1026 patients, 235 had a BCR (23%). Patients with a low ANN value (below the chosen cutoff) had only 16.5% of the 768 BCR <ref type="table" target="#tab_2">(Table 4</ref>). But if patients had an ANN value above the cutoff, 41.9% showed BCR. This rate is almost doubled in comparison to the 23% without considering the ANN output value and almost tripled in comparison to the group below the cutoff. However, analysis of individual ANN output values had no benefit in patients with GS &lt;7 PCa, where only 40 patients had a BCR.</p><p>When further analyzing the 260 patients with highly aggressive PCa and a GS &gt; 7, the overall BCR rate of 43.5% (113 of 260). This rate dropped when the ANN value was below the cutoff. Only 28 of 96 patients (29.2%) had a BCR. In contrast, those patients with aggressive PCa and high ANN values had a &gt;50% likelihood to have a BCR (51.8%; 85 of 164). This individual risk estimation could support further treatment, especially in patients with high GS and high ANN values compared with lower risk patients.</p><p>Uniquely, our calculated models at every 6 months following surgery can provide the individual BCR free probability at individual  time-points after a BCR free period. For example, as shown in <ref type="figure" target="#fig_1">Figure 2b</ref>, a patient with a GS of 7 and a recurrence free survival of 3 years after LRP only has an 8% likelihood of a BCR up to 5 years, and 14% up to 7.5 years <ref type="figure" target="#fig_1">(Figure 2c)</ref>. Without considering the three BCR free years, the estimated BCR risk would be ~22%. This allows for a more optimistic prognosis in comparison to those values calculating risk only immediately after prostatectomy. A limitation of this study is the availability of only internal validation results for all models. However, our aim was to demonstrate the possibility of improving individual BCR estimation at any point after LRP. Another limitation was the decreased available patient data with increased follow-up time.</p><p>Nevertheless, patient's age, PSA, and GS were found to play a distinct role in PCa prognosis. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32</ref> Currently, those prediction parameters and the ANN output value best predict a PCa recurrence. Further, with our ANN models, this prediction can be made for an individual time point after LRP and with patients who have BCR free time-points. Other parameters such as %fPSA or the margin status did not contribute as speculated before. The %fPSA performs well in PCa diagnosis, but is less competitive in the prognosis of PCa or BCR, therefore it is not used in our models.   </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc>Receiver operating characteristic curves for the models: artificial neural network (area under ROC curve [AUC] 0.754) and logistic regression (AUC 0.755) and the variables Gleason Score (AUC 0.715) and prostatespecific antigen (AUC 0.619).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 :</head><label>2</label><figDesc>Probability of recurrence-free survival at 2.5, 5, and 7.5 years after laparoscopic radical prostatectomy (LRP) according to Gleason score (above three figures) and artificial neural network output (below three figures). The curves are based on Kaplan-Meier curves computed every 6 months after LRP for patients which are under investigation, that is, patients without biochemical recurrence or not censored patients.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 : Clinical characteristics of the study population a</head><label>1</label><figDesc>: interquartile range; BCR: biochemical recurrence; DRE: digital rectal examination; %fPSA: percent free PSA; PSA: prostate-specific antigen; PV: prostate volume; R1: margin status. a Values in parentheses are IQRs or percentages of patients' number;</figDesc><table><row><cell>Characteristics</cell><cell>Total</cell><cell>Non-BCR</cell><cell>BCR</cell><cell>P</cell></row><row><cell>Number</cell><cell>1575</cell><cell>1300</cell><cell>275</cell><cell></cell></row><row><cell>Age (year)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>63</cell><cell>63</cell><cell>63</cell><cell>0.374 b</cell></row><row><cell>(IQR 25%-75%)</cell><cell>(59-66)</cell><cell>(59-66)</cell><cell>(59-67)</cell><cell></cell></row><row><cell>Range</cell><cell>43-75</cell><cell>43-75</cell><cell>43-75</cell><cell></cell></row><row><cell>PSA (ng ml −1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>7.5</cell><cell>7.5</cell><cell>7.5</cell><cell>0.115 b</cell></row><row><cell>(IQR 25%-75%)</cell><cell>(5.3-11.0)</cell><cell>(5.2-10.4)</cell><cell>(6.3-14.1)</cell><cell></cell></row><row><cell>Range</cell><cell>1.3-50.7</cell><cell>1.3-50.7</cell><cell>1.7-50.6</cell><cell></cell></row><row><cell>%fPSA</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>9.35</cell><cell>9.60</cell><cell>8.0</cell><cell>0.257 b</cell></row><row><cell>(IQR 25%-75%)</cell><cell>(6.51-13.1)</cell><cell>(6.67-13.4)</cell><cell>(6.07-11.6)</cell><cell></cell></row><row><cell>Range</cell><cell>1.18-41.2</cell><cell>1.18-41.2</cell><cell>1.57-27.0</cell><cell></cell></row><row><cell>PV (ml)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>35</cell><cell>35</cell><cell>30</cell><cell>0.334 b</cell></row><row><cell>(IQR 25%-75%)</cell><cell>(26-47)</cell><cell>(26-48)</cell><cell>(25-42)</cell><cell></cell></row><row><cell>Range</cell><cell>7-190</cell><cell>7-190</cell><cell>12-105</cell><cell></cell></row><row><cell>PSA density</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>0.21</cell><cell>0.20</cell><cell>0.29</cell><cell>0.108 b</cell></row><row><cell>(IQR 25%-75%)</cell><cell>(0.14-0.33)</cell><cell>(0.13-0.31)</cell><cell>(0.18-0.44)</cell><cell></cell></row><row><cell>Range</cell><cell>0.02-1.66</cell><cell>0.02-1.66</cell><cell>0.04-1.64</cell><cell></cell></row><row><cell>DRE positive</cell><cell>548</cell><cell>410</cell><cell>138</cell><cell>&lt;0.0001 c</cell></row><row><cell>R1=1</cell><cell>488</cell><cell>341</cell><cell>147</cell><cell>&lt;0.0001 c</cell></row><row><cell>Gleason, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Gleason&lt;7</cell><cell>549 (35)</cell><cell>509 (39)</cell><cell>40 (15)</cell><cell>&lt;0.0001 c</cell></row><row><cell>Gleason=7</cell><cell>766 (49)</cell><cell>644 (50)</cell><cell>122 (44)</cell><cell></cell></row><row><cell>Gleason&gt;7</cell><cell>260 (16)</cell><cell>147 (11)</cell><cell>113 (41)</cell><cell></cell></row><row><cell>pT, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pT=2</cell><cell>1119 (71)</cell><cell>1004 (77)</cell><cell>115 (42)</cell><cell>&lt;0.0001 c</cell></row><row><cell>pT=3</cell><cell>446 (28)</cell><cell>292 (22)</cell><cell>154 (56)</cell><cell></cell></row><row><cell>pT=4</cell><cell>10 (1)</cell><cell>4 (1)</cell><cell>6 (2)</cell><cell></cell></row></table><note>IQRb Mann-Whitney U test; c Fisher's exact test</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 : ROC analysis with prediction results at 90% sensitivity and 95% sensitivity</head><label>2</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">90% sensitivity</cell><cell cols="2">95% sensitivity</cell><cell>AUC</cell><cell>95% CI a</cell></row><row><cell></cell><cell>Specificity</cell><cell>CI</cell><cell>Specificity</cell><cell>CI</cell></row><row><cell>ANN</cell><cell>35.1</cell><cell>32.6-37.8</cell><cell>20</cell><cell cols="2">17.9-22.3 0.754 0.721-0.786</cell></row><row><cell>LR</cell><cell>36.5</cell><cell>33.9-39.2</cell><cell>18.8</cell><cell cols="2">16.8-21.1 0.755 0.723-0.787</cell></row><row><cell>GS</cell><cell>NA</cell><cell></cell><cell>8.92</cell><cell cols="2">7.4-10.6 0.715 0.680-0.750</cell></row><row><cell>PSA</cell><cell>18.6</cell><cell>16.5-20.8</cell><cell>8.46</cell><cell cols="2">7.0-10.1 0.619 0.582-0.657</cell></row></table><note>GS: Gleason score; ROC: receiver operating characteristic; ANN: artificial neural network; AUC: area under ROC curve; CI: confidence interval; LR: logistic regression; PSA, prostate-specific antigen.a 95% CI of the respective AUC</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 4 )</head><label>4</label><figDesc>. Of the 768 patients with an ANN value below the median cutoff, only 16.5% (n = 127) developed BCR. On the other hand, of the 258 patients with an ANN value above the median cutoff, 41.9% (n = 108) developed BCR. Further analysis of the 260 patients with a GS &gt;7 showed an overall BCR rate of 43.5% (113 of 260) that dropped tremendously when the ANN value was below the cutoff. Only 28 of 96 patients (29.2%) had a BCR. Interestingly, among patients with aggressive PCa and high ANN values, 51.8% had a BCR (85 of 164).</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 : Pairwise comparison of prediction methods</head><label>3</label><figDesc></figDesc><table><row><cell>Pairwise comparisons methods</cell><cell>ANN versus LR</cell><cell>ANN versus Gleason</cell><cell>ANN versus PSA</cell><cell>LR versus Gleason</cell><cell>LR versus PSA</cell><cell>Gleason versus PSA</cell></row><row><cell>AUC difference between areas</cell><cell>0.001</cell><cell>0.039</cell><cell>0.134</cell><cell>0.040</cell><cell>0.136</cell><cell>0.096</cell></row><row><cell>95% CIs</cell><cell>0.002-0.005</cell><cell>0.014-0.063</cell><cell>0.093-0.175</cell><cell>0.016-0.064</cell><cell>0.095-0.177</cell><cell>0.048-0.143</cell></row><row><cell>P a</cell><cell>0.39</cell><cell>0.0015</cell><cell>&lt;0.0001</cell><cell>0.0001</cell><cell>&lt;0.0001</cell><cell>0.0001</cell></row></table><note>ROC: receiver operating characteristic; CI: confidence interval; ANN: artificial neural network; AUC: area under ROC curve; LR: logistic regression; PSA: prostate-specific antigen;a Delong test</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5 : Comparison of ANNs with different parameters</head><label>5</label><figDesc></figDesc><table><row><cell>Study</cell><cell>No. of</cell><cell>Variables</cell><cell>Sensitivity</cell><cell>Specificity</cell><cell>Accuracy</cell><cell>AUC</cell></row><row><cell></cell><cell>patients</cell><cell></cell><cell>(%)</cell><cell>(%)</cell><cell>(%)</cell><cell></cell></row><row><cell>Tewari</cell><cell cols="2">1280 Age, PSA, systematic</cell><cell>76</cell><cell>85</cell><cell>76</cell><cell>0.831</cell></row><row><cell>et al. 7</cell><cell></cell><cell>biopsy-based,</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>stage, perineural</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>infiltration, GS,</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>duration of follow-up</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>in months</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ziada</cell><cell cols="2">309 TNM stage, prostate</cell><cell>79</cell><cell>81</cell><cell>80</cell><cell></cell></row><row><cell>et al. 29</cell><cell></cell><cell>size, PSA, GS,</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>percentage of</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>positive biopsy, age</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Potter</cell><cell cols="2">214 GS, extraprostatic</cell><cell>88.2</cell><cell>61.1</cell><cell cols="2">74.3 0.713</cell></row><row><cell>et al. 26</cell><cell></cell><cell>extension, surgical</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>margin status, age</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Potter</cell><cell cols="2">214 DNA ploidy, the</cell><cell>74.5</cell><cell>85.2</cell><cell>80.0</cell><cell>0.74</cell></row><row><cell>et al. 26</cell><cell></cell><cell>variance of 41</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>different nuclear</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>morphometric</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>descriptors</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Potter</cell><cell cols="2">214 GS, extraprostatic</cell><cell>84.3</cell><cell>72.2</cell><cell cols="2">78.1 0.735</cell></row><row><cell>et al. 26</cell><cell></cell><cell>extension, surgical</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>margin status,</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>age, DNA ploidy,</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>QNG (the variance of</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>41 different nuclear</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>morphometric</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>descriptors)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Porter</cell><cell cols="2">196 Biopsy primary,</cell><cell>74</cell><cell>78</cell><cell>81</cell><cell>0.80</cell></row><row><cell>et al. 28</cell><cell></cell><cell>secondary Gleason</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>grade, biopsy GS,</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>age, PSA</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Present</cell><cell cols="2">1575 Age, PSA, GS</cell><cell>40.7</cell><cell>87.5</cell><cell cols="2">79.3 0.754</cell></row><row><cell>study</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note>ROC: receiver operating characteristic; ANN: artificial neural network; AUC: area under ROC curve; GS: Gleason score; LR: logistic regression; PSA: prostate-specific antigen; QNG: quantitative nuclear grade, TNM: tumor, node, metastases, DNA: deoxyribonucleic acid</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 4 : Proportion of patients with biochemical recurrence depending of Gleason score and artificial neural network output</head><label>4</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">No. patients (n) Patients with BCR (n, %)</cell><cell>P a</cell></row><row><cell>GS 7-10</cell><cell>1026</cell><cell>235 (22.9)</cell><cell></cell></row><row><cell>ANN</cell><cell>768</cell><cell>127 (16.5)</cell><cell>&lt;0.00001</cell></row><row><cell>output&lt;cutoff</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ANN</cell><cell>258</cell><cell>108 (41.9)</cell><cell></cell></row><row><cell>output≥cutoff</cell><cell></cell><cell></cell><cell></cell></row><row><cell>GS 8-10</cell><cell>260</cell><cell>113 (43.5)</cell><cell></cell></row><row><cell>ANN</cell><cell>96</cell><cell>28 (29.2)</cell><cell>0.0006</cell></row><row><cell>output&lt;cutoff</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ANN</cell><cell>164</cell><cell>85 (51.8)</cell><cell></cell></row><row><cell>output≥cutoff</cell><cell></cell><cell></cell><cell></cell></row></table><note>ANN: artificial neural network; BCR: biochemical recurrence; GS: Gleason score.a Calculated by Fisher's exact test</note></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSION</head><p>The predictive ability of our ANN and LR models is better than single standard parameters GS and PSA. Our models for individual BCR free probability at individual time-points after a BCR free period offer an individual BCR prediction. By combining the GS and ANN output value, a BCR prediction is more accurate and may lead to a more accurate application of adjuvant therapy after prostatectomy especially in high-risk patients with GS ≥7.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHOR CONTRIBUTIONS</head><p>CS, JB, HC, HAM, and KJ took part in conception and design, in acquisition, analysis, and interpretation of data. XHH and HBL took part in acquisition, analysis, and interpretation of data. NL and AM took part in the acquisition of data. All authors took part in drafting and revising the manuscript. All authors read and approved the final version of the manuscript.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>COMPETING INTERESTS</head><p>The authors declare no competing interests.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p>This study was supported by a grant of the Berliner Sparkassenstiftung Medizin (Grant No. 89838600).</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Oncologic Outcome after Laparoscopic Radical Prostatectomy: 10 Years of Experience</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karim</forename><surname>Touijer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fernando</forename><forename type="middle">P</forename><surname>Secin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Angel</forename><forename type="middle">M</forename><surname>Cronin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Darren</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fernando</forename><surname>Bianco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kinjal</forename><surname>Vora</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Victor</forename><surname>Reuter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">J</forename><surname>Vickers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bertrand</forename><surname>Guillonneau</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2008.10.036</idno>
		<idno type="PMID">19013010</idno>
		<idno type="PMCID">PMC2962532</idno>
	</analytic>
	<monogr>
		<title level="j">European Urology</title>
		<title level="j" type="abbrev">European Urology</title>
		<idno type="ISSN">0302-2838</idno>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1014" to="1019" />
			<date type="published" when="2009-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Laparoscopic radical prostatectomy: oncological and functional results of 126 patients with a minimum 3-year follow-up at a single Chinese institute</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xin</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian-Hua</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Liao-Yuan</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian-Guang</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiao-Yong</forename><surname>Pu</surname></persName>
		</author>
		<idno type="DOI">10.1038/aja.2009.42</idno>
		<idno type="PMID">19648935</idno>
		<idno type="PMCID">PMC3735014</idno>
		<ptr type="open-access" target="http://www.asiaandro.com/news/upload/20130627-aja200942a.pdf" />
	</analytic>
	<monogr>
		<title level="j">Asian Journal of Andrology</title>
		<title level="j" type="abbrev">Asian J Androl</title>
		<idno type="ISSN">1008-682X</idno>
		<idno type="ISSNe">1745-7262</idno>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="548" to="556" />
			<date type="published" when="2009-08-03" />
			<publisher>Medknow</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Natural History of Progression After PSA Elevation Following Radical Prostatectomy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">R</forename><surname>Pound</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">W</forename><surname>Partin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Eisenberger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">W</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Pearson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">C</forename><surname>Walsh</surname></persName>
		</author>
		<idno type="DOI">10.1097/00005392-199910000-00103</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Urology</title>
		<title level="j" type="abbrev">The Journal of Urology</title>
		<idno type="ISSN">0022-5347</idno>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope unit="page">1548</biblScope>
			<date type="published" when="1999-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">V</forename><surname>D'amico</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Moul</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">R</forename><surname>Carroll</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Lubeck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M-H</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djg043</idno>
		<idno type="PMID">13130113</idno>
		<idno type="PII">1460-2105</idno>
		<idno type="ark">ark:/67375/HXZ-C4LBBXR7-V</idno>
		<idno type="istexId">50CE7BB1C84579F33DAD535A713E9A904BD18296</idno>
		<ptr type="open-access" target="https://academic.oup.com/jnci/article-pdf/95/18/1376/9835530/1376.pdf" />
	</analytic>
	<monogr>
		<title level="j">JNCI Journal of the National Cancer Institute</title>
		<title level="j" type="abbrev">JNCI Journal of the National Cancer Institute</title>
		<idno type="ISSN">0027-8874</idno>
		<idno type="ISSNe">1460-2105</idno>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="1376" to="1383" />
			<date type="published" when="2003-09-16" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hui-Jie</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yang</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin-Guo</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ling</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hai-Tao</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xue-Jian</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masaaki</forename><surname>Kuwahara</surname></persName>
		</author>
		<idno type="DOI">10.1038/aja.2012.130</idno>
		<idno type="PMID">23334201</idno>
		<idno type="PMCID">PMC3739147</idno>
		<ptr type="open-access" target="http://www.asiaandro.com/news/upload/20130912-aja2012130a.pdf" />
	</analytic>
	<monogr>
		<title level="j">Asian Journal of Andrology</title>
		<title level="j" type="abbrev">Asian J Androl</title>
		<idno type="ISSN">1008-682X</idno>
		<idno type="ISSNe">1745-7262</idno>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="218" to="220" />
			<date type="published" when="2013-01-21" />
			<publisher>Medknow</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">W</forename><surname>Kattan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alan</forename><forename type="middle">M F</forename><surname>Stapleton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><forename type="middle">M</forename><surname>Wheeler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><forename type="middle">T</forename><surname>Scardino</surname></persName>
		</author>
		<idno type="DOI">10.1002/(sici)1097-0142(19970201)79:3&lt;528::aid-cncr15&gt;3.3.co;2-d</idno>
		<idno type="PMID">9028364</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<title level="j" type="abbrev">Cancer</title>
		<idno type="ISSN">0008-543X</idno>
		<idno type="ISSNe">1097-0142</idno>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="528" to="537" />
			<date type="published" when="1997-02-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Genetic Adaptive Neural Network to Predict Biochemical Failure After Radical Prostatectomy: A Multi-institutional Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ashutosh</forename><surname>Tewari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mutta</forename><surname>Issa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rizk</forename><surname>El-Galley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hans</forename><surname>Stricker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><surname>Peabody</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julio</forename><surname>Pow-Sang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Asim</forename><surname>Shukla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zev</forename><surname>Wajsman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><surname>Rubin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><surname>Montie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raymond</forename><surname>Demers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christine</forename><forename type="middle">C</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lois</forename><surname>Lamerato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">George</forename><forename type="middle">W</forename><surname>Divine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">David</forename><surname>Crawford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eduard</forename><forename type="middle">J</forename><surname>Gamito</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Riad</forename><surname>Farah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Perinchery</forename><surname>Narayan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Grant</forename><surname>Carlson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mani</forename><surname>Menon</surname></persName>
		</author>
		<idno type="DOI">10.1089/10915360152745849</idno>
		<idno type="PMID">11790278</idno>
		<ptr type="open-access" target="https://deepblue.lib.umich.edu/bitstream/2027.42/63438/1/10915360152745849.pdf" />
	</analytic>
	<monogr>
		<title level="j">Molecular Urology</title>
		<title level="j" type="abbrev">Molecular Urology</title>
		<idno type="ISSN">1091-5362</idno>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="163" to="169" />
			<date type="published" when="2001-12" />
			<publisher>Mary Ann Liebert Inc</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Artificial neural networks improve the accuracy of cancer survival prediction</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harry</forename><forename type="middle">B</forename><surname>Burke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philip</forename><forename type="middle">H</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">B</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donald</forename><forename type="middle">E</forename><surname>Henson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">N</forename><surname>Weinstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Frank</forename><forename type="middle">E</forename><surname>Harrell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeffrey</forename><forename type="middle">R</forename><surname>Marks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">P</forename><surname>Winchester</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">G</forename><surname>Bostwick</surname></persName>
		</author>
		<idno type="DOI">10.1002/(sici)1097-0142(19970215)79:4&lt;857::aid-cncr24&gt;3.0.co;2-y</idno>
		<idno type="PMID">9024725</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<title level="j" type="abbrev">Cancer</title>
		<idno type="ISSN">0008-543X</idno>
		<idno type="ISSNe">1097-0142</idno>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="857" to="862" />
			<date type="published" when="1997-02-15" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Image-based clinical decision support for transrectal ultrasound in the diagnosis of prostate cancer: comparison of multiple logistic regression, artificial neural network, and support vector machine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hak</forename><forename type="middle">Jong</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sung</forename><forename type="middle">Il</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seok-Min</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seong</forename><forename type="middle">Ho</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung</forename><forename type="middle">Hyup</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeong</forename><forename type="middle">Yeon</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chang</forename><forename type="middle">Gyu</forename><surname>Seong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gheeyoung</forename><surname>Choe</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00330-009-1686-x</idno>
		<idno type="PMID">20016902</idno>
		<idno type="ark">ark:/67375/VQC-0B3JF1NQ-N</idno>
		<idno type="istexId">6E22B3329D2509724E3C0F5493890DE249411391</idno>
	</analytic>
	<monogr>
		<title level="j">European Radiology</title>
		<title level="j" type="abbrev">Eur Radiol</title>
		<idno type="ISSN">0938-7994</idno>
		<idno type="ISSNe">1432-1084</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1476" to="1484" />
			<date type="published" when="2009-12-17" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Preoperative Neural Network Using Combined Magnetic Resonance Imaging Variables, Prostate Specific Antigen, and Gleason Score to Predict Prostate Cancer Recurrence after Radical Prostatectomy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vassilis</forename><surname>Poulakis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ulrich</forename><surname>Witzsch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rachelle</forename><surname>De Vries</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Volker</forename><surname>Emmerlich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Meves</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hans-Michael</forename><surname>Altmannsberger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eduard</forename><surname>Becht</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2004.07.010</idno>
		<idno type="PMID">15474265</idno>
	</analytic>
	<monogr>
		<title level="j">European Urology</title>
		<title level="j" type="abbrev">European Urology</title>
		<idno type="ISSN">0302-2838</idno>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="571" to="578" />
			<date type="published" when="2004-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">New markers and multivariate models for prostate cancer detection</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Stephan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Rittenhouse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Cammann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Lein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Schrader</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2589" to="600" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Editorial Comment on: Development, Validation, and Head-to-Head Comparison of Logistic Regression-Based Nomograms and Artificial Neural Network Models Predicting Prostate Cancer on Initial Extended Biopsy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">W</forename><surname>Kattan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2008.01.018</idno>
		<idno type="PMID">18207318</idno>
	</analytic>
	<monogr>
		<title level="j">European Urology</title>
		<title level="j" type="abbrev">European Urology</title>
		<idno type="ISSN">0302-2838</idno>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">611</biblScope>
			<date type="published" when="2008-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Comparison of methods for prediction of prostate cancer in Turkish men with PSA levels of 0-10 ng/mL</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">H</forename><surname>Gulkesen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">T</forename><surname>Koksal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Bilge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Saka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J BUON</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="537" to="579" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carsten</forename><surname>Stephan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chuanliang</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">A</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Samuel</forename><forename type="middle">N</forename><surname>Breit</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anja</forename><surname>Michael</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Terukazu</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eleftherios</forename><forename type="middle">P</forename><surname>Diamandis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hellmuth</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Henning</forename><surname>Cammann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Klaus</forename><surname>Jung</surname></persName>
		</author>
		<idno type="DOI">10.1002/pros.20381</idno>
		<idno type="PMID">16388506</idno>
		<idno type="ark">ark:/67375/WNG-NGTBVPJS-7</idno>
		<idno type="istexId">0E78700BCA2BEE58B26F91D88D60BADC45D4A24C</idno>
	</analytic>
	<monogr>
		<title level="j">The Prostate</title>
		<title level="j" type="abbrev">Prostate</title>
		<idno type="ISSN">0270-4137</idno>
		<idno type="ISSNe">1097-0045</idno>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="651" to="659" />
			<date type="published" when="2006-05-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Comparation of Artificial Neural Network and Logistic Regression Models for Predicting Clinically Relevant Outcome</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stevo</forename><surname>Lukić</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Žarko</forename><surname>Ćojbašić</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zoran</forename><surname>Milošević</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.wneu.2012.07.005</idno>
		<idno type="PMID">22796393</idno>
	</analytic>
	<monogr>
		<title level="j">World Neurosurgery</title>
		<title level="j" type="abbrev">World Neurosurgery</title>
		<idno type="ISSN">1878-8750</idno>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">1-2</biblScope>
			<biblScope unit="page" from="e377" to="e378" />
			<date type="published" when="2014-07" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Comparation of artificial neural network and logistic regression models for predicting clinically relevant outcome</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">I</forename><surname>Rughani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">I</forename><surname>Tranmer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">M</forename><surname>Dumont</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.wneu.2012.07.006</idno>
	</analytic>
	<monogr>
		<title level="j">World Neurosurg</title>
		<imprint>
			<date type="published" when="2012-07-13" />
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hideaki</forename><surname>Miyake</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masato</forename><surname>Fujisawa</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1442-2042.2012.03175.x</idno>
		<idno type="PMID">23020893</idno>
		<idno type="ark">ark:/67375/WNG-2CQ04HNX-J</idno>
		<idno type="istexId">C3774E390616C4EC0E146E00DC7632CD985C5880</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Urology</title>
		<title level="j" type="abbrev">Int J Urol</title>
		<idno type="ISSN">0919-8172</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="301" to="311" />
			<date type="published" when="2012-09-30" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Modeling Medical Prognosis: Survival Analysis Techniques</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lucila</forename><surname>Ohno-Machado</surname></persName>
		</author>
		<idno type="DOI">10.1006/jbin.2002.1038</idno>
		<idno type="PMID">12198763</idno>
		<idno type="PII">S1532-0464(02)91038-5</idno>
		<idno type="ark">ark:/67375/6H6-T5WT2VT4-Q</idno>
		<idno type="istexId">735F437C230A1CD4237B7C189E7D253701EBCDE6</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Biomedical Informatics</title>
		<title level="j" type="abbrev">Journal of Biomedical Informatics</title>
		<idno type="ISSN">1532-0464</idno>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="428" to="439" />
			<date type="published" when="2001-12" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">B</forename><surname>Edge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carolyn</forename><forename type="middle">C</forename><surname>Compton</surname></persName>
		</author>
		<idno type="DOI">10.1245/s10434-010-0985-4</idno>
		<idno type="PMID">20180029</idno>
		<idno type="ark">ark:/67375/VQC-GQ80DQ98-P</idno>
		<idno type="istexId">9C7F978F19F2862AD4A783F6A1AE5D2357DAF81F</idno>
		<ptr type="open-access" target="https://link.springer.com/content/pdf/10.1245%2Fs10434-010-0985-4.pdf" />
	</analytic>
	<monogr>
		<title level="j">Annals of Surgical Oncology</title>
		<title level="j" type="abbrev">Ann Surg Oncol</title>
		<idno type="ISSN">1068-9265</idno>
		<idno type="ISSNe">1534-4681</idno>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1471" to="1474" />
			<date type="published" when="2010-02-24" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">ISUP Grading Committee</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">I</forename><surname>Epstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">C</forename><surname>Allsbrook</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">B</forename><surname>Amin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">L</forename><surname>Egevad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma</title>
		<imprint>
			<date type="published" when="2005" />
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1228" to="1270" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Douglas</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lisa</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Willi</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sheila</forename><forename type="middle">E</forename><surname>Taube</surname></persName>
		</author>
		<idno type="DOI">10.1186/1741-7015-10-51</idno>
		<idno type="PMID">22642691</idno>
		<idno type="PMCID">PMC3362748</idno>
		<ptr type="open-access" target="https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/1741-7015-10-51" />
	</analytic>
	<monogr>
		<title level="j">BMC Medicine</title>
		<title level="j" type="abbrev">BMC Med</title>
		<idno type="ISSNe">1741-7015</idno>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">1001216</biblScope>
			<date type="published" when="2012-05-29" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Stephan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Cammann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Semjonow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">P</forename><surname>Diamandis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">F</forename><surname>Wymenga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1279" to="87" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">An artificial neural network to predict the outcome of repeat prostate biopsies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mesut</forename><surname>Remzi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Theodore</forename><surname>Anagnostou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vincent</forename><surname>Ravery</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexandre</forename><surname>Zlotta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carsten</forename><surname>Stephan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Marberger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bob</forename><surname>Djavan</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0090-4295(03)00409-6</idno>
		<idno type="PMID">12946746</idno>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<title level="j" type="abbrev">Urology</title>
		<idno type="ISSN">0090-4295</idno>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="456" to="460" />
			<date type="published" when="2003-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joseph</forename><forename type="middle">T</forename><surname>Batuello</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eduard</forename><forename type="middle">J</forename><surname>Gamito</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">David</forename><surname>Crawford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Misop</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alan</forename><forename type="middle">W</forename><surname>Partin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">G</forename><surname>Mcleod</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Colin</forename><surname>O’donnell</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0090-4295(00)01039-6</idno>
		<idno type="PMID">11248624</idno>
		<idno type="PII">S0090-4295(00)01039-6</idno>
		<idno type="ark">ark:/67375/6H6-G34QQLHG-D</idno>
		<idno type="istexId">3DD5552A74A9908204C6A1F85CD8EA0057014407</idno>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<title level="j" type="abbrev">Urology</title>
		<idno type="ISSN">0090-4295</idno>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="481" to="485" />
			<date type="published" when="2001-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Artificial neural networks in clinical urology</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><forename type="middle">B</forename><surname>Snow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">M</forename><surname>Rodvold</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeffrey</forename><forename type="middle">M</forename><surname>Brandt</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0090-4295(99)00327-1</idno>
		<idno type="PMID">10565734</idno>
		<idno type="PII">S0090-4295(99)00327-1</idno>
		<idno type="ark">ark:/67375/6H6-N9D06854-D</idno>
		<idno type="istexId">C0113A1114145D427AA86A4B327900F208FD386C</idno>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<title level="j" type="abbrev">Urology</title>
		<idno type="ISSN">0090-4295</idno>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="787" to="790" />
			<date type="published" when="1999-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><forename type="middle">R</forename><surname>Potter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Craig</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leslie</forename><forename type="middle">A</forename><surname>Mangold</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kerrie</forename><forename type="middle">A</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jonathan</forename><forename type="middle">I</forename><surname>Epstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">W</forename><surname>Veltri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alan</forename><forename type="middle">W</forename><surname>Partin</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0090-4295(99)00328-3</idno>
		<idno type="PMID">10565735</idno>
		<idno type="PII">S0090-4295(99)00328-3</idno>
		<idno type="ark">ark:/67375/6H6-FJ73TTTH-1</idno>
		<idno type="istexId">FEB981FD2E0855BA51750374E500171662843C6A</idno>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<title level="j" type="abbrev">Urology</title>
		<idno type="ISSN">0090-4295</idno>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="791" to="795" />
			<date type="published" when="1999-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Artificial Neural Networks in the Diagnosis and Prognosis of Prostate Cancer: A Pilot Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><forename type="middle">B</forename><surname>Snow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deborah</forename><forename type="middle">S</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">William</forename><forename type="middle">J</forename><surname>Catalona</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0022-5347(17)32416-3</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Urology</title>
		<title level="j" type="abbrev">The Journal of Urology</title>
		<idno type="ISSN">0022-5347</idno>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1923" to="1926" />
			<date type="published" when="1994-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Artificial Neural Network Model To Predict Biochemical Failure After Radical Prostatectomy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christopher</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Colin</forename><surname>O'donnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">David</forename><surname>Crawford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eduard</forename><forename type="middle">J</forename><surname>Gamito</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Abelardo</forename><surname>Errejon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elizabeth</forename><surname>Genega</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tiffany</forename><surname>Sotelo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ashutosh</forename><surname>Tewari</surname></persName>
		</author>
		<idno type="DOI">10.1089/10915360152745830</idno>
		<idno type="PMID">11790277</idno>
	</analytic>
	<monogr>
		<title level="j">Molecular Urology</title>
		<title level="j" type="abbrev">Molecular Urology</title>
		<idno type="ISSN">1091-5362</idno>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="159" to="162" />
			<date type="published" when="2001-12" />
			<publisher>Mary Ann Liebert Inc</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Ziada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">C</forename><surname>Lisle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">B</forename><surname>Snow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">F</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="1653" to="60" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Molecular forms of prostatespecific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Stephan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Lein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Sinha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Schnorr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiol Biomarkers Prev</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1133" to="1180" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Identification of prostate cancer risk categories according to surgical margins status, pathological stage and Gleason score</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Riccardo</forename><surname>Schiavina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marco</forename><surname>Borghesi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michelangelo</forename><surname>Fiorentino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eugenio</forename><surname>Brunocilla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fabio</forename><surname>Manferrari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Valerio</forename><surname>Vagnoni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giuseppe</forename><surname>Martorana</surname></persName>
		</author>
		<idno type="DOI">10.1111/iju.12124</idno>
		<idno type="PMID">23521710</idno>
		<idno type="ark">ark:/67375/WNG-KZG7MD23-N</idno>
		<idno type="istexId">9BCBC9F99AB097C5BC069E20E3E331B799A1A9A5</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Urology</title>
		<title level="j" type="abbrev">Int J Urol</title>
		<idno type="ISSN">0919-8172</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1097" to="1103" />
			<date type="published" when="2013-03-21" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Editorial Comment to Identification of prostate cancer risk categories according to surgical margins status, pathological stage and Gleason score</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shinya</forename><surname>Yamamoto</surname></persName>
		</author>
		<idno type="DOI">10.1111/iju.12134</idno>
		<idno type="PMID">23520996</idno>
		<idno type="ark">ark:/67375/WNG-M7GW8J8P-M</idno>
		<idno type="istexId">4EE02E1DFEFFED9D5AB4D5D7877801E27D672BB2</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Urology</title>
		<title level="j" type="abbrev">Int J Urol</title>
		<idno type="ISSN">0919-8172</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1104" to="1104" />
			<date type="published" when="2013-03-21" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
